ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Zevra Therapeutics Inc

Zevra Therapeutics Inc (ZVRA)

8.49
-0.05
(-0.59%)
Closed December 22 4:00PM
8.72
0.23
(2.71%)
After Hours: 7:23PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
8.72
Bid
8.44
Ask
8.89
Volume
2,543,375
8.343 Day's Range 8.83
4.20 52 Week Range 9.76
Market Cap
Previous Close
8.54
Open
8.43
Last Trade Time
Financial Volume
$ 21,783,831
VWAP
8.5649
Average Volume (3m)
661,212
Shares Outstanding
53,375,932
Dividend Yield
-
PE Ratio
-9.84
Earnings Per Share (EPS)
-0.86
Revenue
27.46M
Net Profit
-46.05M

About Zevra Therapeutics Inc

Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Zevra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZVRA. The last closing price for Zevra Therapeutics was $8.54. Over the last year, Zevra Therapeutics shares have traded in a share price range of $ 4.20 to $ 9.76.

Zevra Therapeutics currently has 53,375,932 shares outstanding. The market capitalization of Zevra Therapeutics is $455.83 million. Zevra Therapeutics has a price to earnings ratio (PE ratio) of -9.84.

ZVRA Latest News

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

CELEBRATION, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...

Zevra Therapeutics Announces Organizational Changes

CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...

Zevra Therapeutics to Participate at Upcoming Investor Conferences

CELEBRATION, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the...

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™, Zevra’s comprehensive patient support program...

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received rare pediatric disease Priority Review Voucher...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.333.933253873668.398.798.174805138.44248782CS
4-0.52-5.627705627719.249.768.174561699.05196365CS
121.4119.28864569087.319.766.616612128.38807723CS
264.2795.95505617984.459.764.28174677.59326431CS
523.8277.95918367354.99.764.25358797.14541201CS
1563.0754.33628318585.659.763.893940606.62128957CS
2603.0754.33628318585.659.763.893940606.62128957CS

ZVRA - Frequently Asked Questions (FAQ)

What is the current Zevra Therapeutics share price?
The current share price of Zevra Therapeutics is $ 8.72
How many Zevra Therapeutics shares are in issue?
Zevra Therapeutics has 53,375,932 shares in issue
What is the market cap of Zevra Therapeutics?
The market capitalisation of Zevra Therapeutics is USD 455.83M
What is the 1 year trading range for Zevra Therapeutics share price?
Zevra Therapeutics has traded in the range of $ 4.20 to $ 9.76 during the past year
What is the PE ratio of Zevra Therapeutics?
The price to earnings ratio of Zevra Therapeutics is -9.84
What is the cash to sales ratio of Zevra Therapeutics?
The cash to sales ratio of Zevra Therapeutics is 16.5
What is the reporting currency for Zevra Therapeutics?
Zevra Therapeutics reports financial results in USD
What is the latest annual turnover for Zevra Therapeutics?
The latest annual turnover of Zevra Therapeutics is USD 27.46M
What is the latest annual profit for Zevra Therapeutics?
The latest annual profit of Zevra Therapeutics is USD -46.05M
What is the registered address of Zevra Therapeutics?
The registered address for Zevra Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Zevra Therapeutics website address?
The website address for Zevra Therapeutics is www.kempharm.com
Which industry sector does Zevra Therapeutics operate in?
Zevra Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
$ 0.24
(65.06%)
354.32M
APTOAptose Biosciences Inc
$ 0.28
(64.51%)
305.1M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.606999
(6.49%)
292.16M
NVDANVIDIA Corporation
$ 134.70
(3.08%)
287.21M
PLTRPalantir Technologies Inc
$ 80.55
(8.54%)
277.63M

Discussion

View Full Feed
Zorax Zorax 6 minutes ago
I wonder if he can type with two thumbs.
happyglass happyglass 7 minutes ago
The new administration is no friend of cannabis imo. I cannot understand why the industry prefers state by state medical over full national legalization. It effectively breaks the market up into 50 little countries and the largest market is limited to 34 million people. That is why I am sticking
OILFF
lakers17 lakers17 10 minutes ago
Some crypto AI thoughts (turn on the volume)

https://x.com/i/status/1870619996684185975
MoneyMaker111 MoneyMaker111 19 minutes ago
$30B+ worth of Archegos swaps expiring (January)

Legacy Bill Hwang short positions in $GME.

UBS absorbed Archegos/Credit Suisse's $GME-short bags.

Look out! This is big. Current administration may have pushed this out to impact the next administration t
GME
awesomed007 awesomed007 20 minutes ago
I thought put you on ignore, lol.
SPZI
copytele copytele 22 minutes ago
RGTI
RGTI
Chiugray Chiugray 23 minutes ago
Nice.
NWBO
copytele copytele 30 minutes ago
GAVE YOU # 25
RGTI
Zorax Zorax 35 minutes ago
The reality is shitface offered him a deal he couldn't refuse. A government job.
ReasearchThis ReasearchThis 41 minutes ago
I really think AXXA Bashers should study in detail.
AXXA's new business plan. In quotes
AXXA has been
"Grossly overlooked
Formally updated company kickbacks
Yearly outstanding updated receipts
Systematically experiencing lasting financials"
AXXA
Think1st Think1st 43 minutes ago
https://finance.yahoo.com/news/exclusive-u-data-center-power-150910487.html
LWLG
devil dog 96 devil dog 96 45 minutes ago
So you think issuing restricted shares that can't have their restriction lifted for another year is how they plan on scamming us when they have had shares restricted that were issued in 2018 that the restriction can be lifted today? You sound like you don't know how the OTC works 🤡 LMAO
ATMH
One11 One11 51 minutes ago
Shoon and Steal ride again! Hi ho!!!
Up the breakout boards we go, ho ho!
Not too smart, not too bright but Shoon and Steal will stay and fight, hi dee ho!
MGON
shajandr shajandr 51 minutes ago
When DAVE MASSEY returns from his extended-stay North Korean intox centers, expect him to kick Brad to DaCurb and retool SIRC's binniss plann to focus on energy drinks, power bars, and lithium/rare earths mining ops. Also expect DAVE to create a new SIRC subsidiary that will build and operate a chai
SIRC
copytele copytele 52 minutes ago
https://youtu.be/cQ7qqzQGHs4
RGTI
Not likely Not likely 56 minutes ago
So at the end of the year you pumpers just add 1 to satisfy your hope?
SPZI
Not likely Not likely 1 hour ago
If Timmy brings in a 'Chinese' company. It will most certainly be a scam.

OTC is absolutely riddled with 'Chinese opportunities'. Always has been.

The 'go to' with OTC scams.


Can't verify or prove it.
EEGI

Your Recent History

Delayed Upgrade Clock